Publication | Closed Access

Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

UrologyMedicinePharmacologyClinical TrialsFirst-line TreatmentPharmacotherapyCancer TreatmentProstatic DiseaseOncology